Literature DB >> 29402599

Pembrolizumab in Combination with Radiotherapy for Metastatic Melanoma - Introducing the PERM Trial.

K Yip1, A Melcher2, K Harrington2, T Illidge3, J Nobes4, A Webster5, D Smith6, P Lorigan3, P Nathan7, J Larkin6.   

Abstract

Entities:  

Year:  2018        PMID： 29402599     DOI： 10.1016/j.clon.2018.01.001

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN： 0936-6555            Impact factor:   4.126


× No keyword cloud information.
  3 in total

Review 1.  Radiotherapy for Melanoma: More than DNA Damage.

Authors:  Susanne J Rogers; Emsad Puric; Brigitte Eberle; Niloy R Datta; Stephan B Bodis
Journal:  Dermatol Res Pract       Date:  2019-04-03

Review 2.  A Tangle of Genomic Aberrations Drives Multiple Myeloma and Correlates with Clinical Aggressiveness of the Disease: A Comprehensive Review from a Biological Perspective to Clinical Trial Results.

Authors:  Mariarosaria Sessa; Francesco Cavazzini; Maurizio Cavallari; Gian Matteo Rigolin; Antonio Cuneo
Journal:  Genes (Basel)       Date:  2020-12-03       Impact factor: 4.096

Review 3.  Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell lung cancer.

Authors:  John Conibear
Journal:  Br J Cancer       Date:  2020-12       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.